Literature DB >> 26689709

Immunosuppressive cells in tumor immune escape and metastasis.

Yang Liu1, Xuetao Cao2.   

Abstract

Tumor immune escape and the initiation of metastasis are critical steps in malignant progression of tumors and have been implicated in the failure of some clinical cancer immunotherapy. Tumors develop numerous strategies to escape immune surveillance or metastasize: Tumors not only modulate the recruitment and expansion of immunosuppressive cell populations to develop the tumor microenvironment or pre-metastatic niche but also switch the phenotype and function of normal immune cells from a potentially tumor-reactive state to a tumor-promoting state. Immunosuppressive cells facilitate tumor immune escape by inhibiting antitumor immune responses and furthermore promote tumor metastasis by inducing immunosuppression, promoting tumor cell invasion and intravasation, establishing a pre-metastatic niche, facilitating epithelial-mesenchymal transition, and inducing angiogenesis at primary tumor or metastatic sites. Numerous translational studies indicate that it is possible to inhibit tumor immune escape and prevent tumor metastasis by blocking immunosuppressive cells and eliminating immunosuppressive mechanisms that are induced by either immunosuppressive cells or tumor cells. Furthermore, many clinical trials targeting immunosuppressive cells have also achieved good outcome. In this review, we focus on the underlying mechanisms of immunosuppressive cells in promoting tumor immune escape and metastasis, discuss our current understanding of the interactions between immunosuppressive cells and tumor cells in the tumor microenvironment, and suggest future research directions as well as potential clinical strategies in cancer immunotherapy.

Entities:  

Keywords:  Cancer immunotherapy; Immune escape; Immunosuppressive cell; Metastasis; Tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 26689709     DOI: 10.1007/s00109-015-1376-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  97 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Helper T cell diversity and plasticity.

Authors:  Kayoko Sato
Journal:  Circ J       Date:  2014-11-08       Impact factor: 2.993

3.  The origin and function of tumor-associated macrophages.

Authors:  Yang Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2014-09-15       Impact factor: 11.530

Review 4.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12.

Authors:  Lorena Hernandez; Tatiana Smirnova; Dmitriy Kedrin; Jeffrey Wyckoff; Liyin Zhu; E Richard Stanley; Dianne Cox; William J Muller; Jeffrey W Pollard; Nico Van Rooijen; Jeffrey E Segall
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 6.  The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2014-08       Impact factor: 28.824

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1.

Authors:  Yanmei Han; Yuan Yang; Zhubo Chen; Zhengping Jiang; Yan Gu; Yanfang Liu; Sheng Xu; Chuan Lin; Zeya Pan; Weiping Zhou; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2014-03-26       Impact factor: 4.599

10.  BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Authors:  Laurent Derré; Jean-Paul Rivals; Camilla Jandus; Sonia Pastor; Donata Rimoldi; Pedro Romero; Olivier Michielin; Daniel Olive; Daniel E Speiser
Journal:  J Clin Invest       Date:  2009-12-28       Impact factor: 14.808

View more
  101 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.

Authors:  Qiuyan Liu; Ha Zhu; Chaoxiong Zhang; Taoyong Chen; Xuetao Cao
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

3.  Integrative strategy for improving cancer immunotherapy.

Authors:  Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2016-05       Impact factor: 4.599

Review 4.  Nanomedicine and macroscale materials in immuno-oncology.

Authors:  Qingxue Sun; Matthias Barz; Bruno G De Geest; Mustafa Diken; Wim E Hennink; Fabian Kiessling; Twan Lammers; Yang Shi
Journal:  Chem Soc Rev       Date:  2019-01-02       Impact factor: 54.564

5.  Value of contrast-enhanced ultrasound area ratio in identifying benign and malignant small breast masses.

Authors:  Wei Wang; Yan Zheng; Xiao-Feng Wu; Dan Zhao; Li-Zhu Hou; Fei Shi; Jin-Jin Liu; Feng-Lin Dong
Journal:  Gland Surg       Date:  2020-10

Review 6.  Vascularized Biomaterials to Study Cancer Metastasis.

Authors:  Katharine R Bittner; Juan M Jiménez; Shelly R Peyton
Journal:  Adv Healthc Mater       Date:  2020-01-24       Impact factor: 9.933

7.  C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer.

Authors:  Minjie Mao; Xiaoli Wei; Hui Sheng; Peidong Chi; Yijun Liu; Xiaoyan Huang; Yifan Xiang; Qianying Zhu; Shan Xing; Wanli Liu
Journal:  Oncol Lett       Date:  2017-10-13       Impact factor: 2.967

Review 8.  Small extracellular vesicles in cancer.

Authors:  Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal:  Bioact Mater       Date:  2021-04-07

Review 9.  The evolving landscape of N6-methyladenosine modification in the tumor microenvironment.

Authors:  Yunru Gu; Xi Wu; Jingxin Zhang; Yuan Fang; Yutian Pan; Yongqian Shu; Pei Ma
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

10.  SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.

Authors:  Patricia Balsas; Luis Veloza; Guillem Clot; Marta Sureda-Gómez; Marta-Leonor Rodríguez; Christos Masaoutis; Gerard Frigola; Alba Navarro; Silvia Beà; Ferran Nadeu; Eva Giné; Armando López-Guillermo; Antonio Martínez; Inmaculada Ribera-Cortada; Pablo Engel; Leticia Quintanilla-Martínez; Wolfram Klapper; Elias Campo; Virginia Amador
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.